• Explore /
  • Poster
  • / A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).

A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).

Abstract Poster

Authors

null

Se Hyun Kim

Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea

Se Hyun Kim , Koung Jin Suh , Seock-Ah Im , Kyung-Hun Lee , Min Hwan Kim , Joohyuk Sohn , Yeon Hee Park , Ji-Yeon Kim , Jae Ho Jeong , Kyoung Eun Lee , In Sil Choi , Kyong Hwa Park , Hee Jun Kim , Eun Kyung Cho , So Yeon Park , Milim Kim , Jee Hyun Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Other Breast Cancer Subtypes

Clinical Trial Registration Number

NCT04061863

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 1098)

DOI

10.1200/JCO.2022.40.16_suppl.1098

Abstract #

1098

Poster Bd #

475

Abstract Disclosures

Similar Posters

First Author: Sara M. Tolaney

First Author: Ying Cheng

First Author: Kohei Shitara

First Author: Tamta Makharadze